AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer ...
Only 4 out of 46 companies inspected showed 100% compliance with Revised Schedule M in Tamil Nadu: Peethaambaran Kunnathoor, Chennai Tuesday, November 19, 2024, 08:00 Hrs [IST] In ...
DGFT overhauls export policy through harmonisation with ITC (HS) 2022 to streamline pharma export process: Shardul Nautiyal, Mumbai Tuesday, November 19, 2024, 08:00 Hrs [IST] Wit ...
In the pharmaceutical industry, ensuring the safety, efficacy, and quality of drugs is an ongoing and intricate process. Independent testing laboratories, like Auriga Research, play a critical role ...
Unified mechanism under FSSAI for nutraceuticals would help rather than having two authorities: Expert: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] A unifi ...
SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...
Augurex Life Sciences, Quest Diagnostics collaborate to improve rheumatoid arthritis diagnosis and management: Vancouver, Canada Monday, November 18, 2024, 16:00 Hrs [IST] Augurex ...
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...
As part of a concerted effort to combat tuberculosis (TB) with a focus on climate change, Molbio Diagnostics, an innovator in global healthcare has contributed a donation of their state-of-the-art TB ...
US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...
EMA encourages companies to submit type I variations for 2024 by end November 2024: Amsterdam, The Netherlands Monday, November 18, 2024, 14:00 Hrs [IST] European Medicines Agency ...